Aug 21, 2023 8:30am EDT Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib
Aug 17, 2023 8:30am EDT Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro
Aug 14, 2023 4:20pm EDT Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
Aug 07, 2023 8:05am EDT Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023
Jun 22, 2023 8:05am EDT Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study
Jun 21, 2023 8:05am EDT Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease
May 16, 2023 7:45am EDT Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease